About Oncopeptides

Company Description

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient quality of life.

Oncopeptides uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

The headquarters is in Stockholm, Sweden, and a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.

Year founded

2000

Served area

Worldwide

Headquarters

Luntmakargatan 46, 7th floor, 11137 Stockholm – Sweden

Shareholder information

Shares outstanding

94,309,267

IPO

Feb. 22, 2017

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.